Read More Pharma Industry News IPS HEART gets third FDA pediatric rare disease designation for ISX9-CPC IPS HEART, a private cell therapy company developing treatments for Duchenne muscular dystrophy and heart failure, announced that… byPallavi MadhirajuJuly 9, 2023